Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors within the central anxious method, conolidine modulates alternate molecular targets. A Science Innovations research located that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR